1. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med. 1979;300(20):1142-7.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232-5.
3. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330(18):1287-94.
4. Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, et al. Blocking PGE2- induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517(7533):209-13.
5. Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 2010;62(2):233-44.
6. Sehayek E, Butbul E, Avner R, Levkovitz H, Eisenberg S. Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors. Eur J Clin Invest. 1994;24(3):173-8.
7. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84(3):413-28.
8. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97(12):1129-35.
9. Simionescu M, Stancu C, Costache G, Sima A. Endothelial cell response to hyperlipemia. Activation-dysfunction-injury, the protective role of simvastatin. Vascul Pharmacol. 2002;38(5):275-82.
10. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92(3):657-71.
11. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998;18(11):1671-8.
12. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med. 2000;32(3):164-76.
13. Goto S, Kato K, Yamamoto T, Shimato S, Ohshima T, Nishizawa T. Effectiveness of Goreisan in Preventing Recurrence of Chronic Subdural Hematoma. Asian J Neurosurg. 2018;13(2):370-4.
14. Yasunaga H. Effect of Japanese Herbal Kampo Medicine Goreisan on Reoperation Rates after Burr-Hole Surgery for Chronic Subdural Hematoma: Analysis of a National Inpatient Database. Evidence-Based Complementary and Alternative Medicine. 2015:6.
15. Yadav YR, Parihar V, Namdev H, Bajaj J. Chronic subdural hematoma. Asian J Neurosurg. 2016;11(4):330-42.
16. Edlmann E, Giorgi-Coll S, Whitfield PC, Carpenter KLH, Hutchinson PJ. Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy. J Neuroinflammation. 2017;14(1):108.
17. Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self- regulating system. J Cell Biol. 1990;111(2):757-63.
18. Shono T, Inamura T, Morioka T, Matsumoto K, Suzuki SO, Ikezaki K, et al. Vascular endothelial growth factor in chronic subdural haematomas. J Clin Neurosci. 2001;8(5):411-5.
19. Li F, Hua C, Feng Y, Yuan H, Bie L. Correlation of vascular endothelial growth factor with magnetic resonance imaging in chronic subdural hematomas. J Neurol Sci. 2017;377:149-54.
20. Isaji T, Osuka K, Ohmichi Y, Ohmichi M, Naito M, Nakano T, et al. Expression of Angiopoietins and Angiogenic Signaling Pathway Molecules in Chronic Subdural Hematomas. J Neurotrauma. 2020;37(23):2493-8.
21. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549-80.
22. Li S, Huang NF, Hsu S. Mechanotransduction in endothelial cell migration. J Cell Biochem. 2005;96(6):1110-26.
23. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res. 2007;100(6):782-94.
24. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011-27.
25. Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer. Cancer Treat Rev. 2004;30(8):715-7.
26. Agre P, King LS, Yasui M, Guggino WB, Ottersen OP, Fujiyoshi Y, et al. Aquaporin water channels--from atomic structure to clinical medicine. J Physiol. 2002;542(Pt 1):3-16.
27. Verkman AS, Mitra AK. Structure and function of aquaporin water channels. Am J Physiol Renal Physiol. 2000;278(1):F13-28.
28. Verkman AS. More than just water channels: unexpected cellular roles of aquaporins. J Cell Sci. 2005;118(Pt 15):3225-32.
29. Kuriyama H, Kawamoto S, Ishida N, Ohno I, Mita S, Matsuzawa Y, et al. Molecular cloning and expression of a novel human aquaporin from adipose tissue with glycerol permeability. Biochem Biophys Res Commun. 1997;241(1):53-8.
30. Ishibashi K, Sasaki S, Fushimi K, Uchida S, Kuwahara M, Saito H, et al. Molecular cloning and expression of a member of the aquaporin family with permeability to glycerol and urea in addition to water expressed at the basolateral membrane of kidney collecting duct cells. Proc Natl Acad Sci U S A. 1994;91(14):6269-73.
31. Ma T, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS. Severely impaired urinary concentrating ability in transgenic mice lacking aquaporin-1 water channels. J Biol Chem. 1998;273(8):4296-9.
32. Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature. 2005;434(7034):786-92.
33. Saadoun S, Papadopoulos MC, Davies DC, Bell BA, Krishna S. Increased aquaporin 1 water channel expression in human brain tumours. Br J Cancer. 2002;87(6):621-3.
34. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003;112(1):67-75.
35. Papadopoulos MC, Saadoun S, Verkman AS. Aquaporins and cell migration. Pflugers Arch. 2008;456(4):693-700.
36. Crawford SE, Ramani S, Tate JE, Parashar UD, Svensson L, Hagbom M, et al. Rotavirus infection. Nat Rev Dis Primers. 2017;3:17083.
37. Gurwith M, Wenman W, Hinde D, Feltham S, Greenberg H. A prospective study of rotavirus infection in infants and young children. J Infect Dis. 1981;144(3):218-24.
38. Velázquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med. 1996;335(14):1022-8.
39. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9(5):565-72.
40. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD, Network WHOCGRS. Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013. Clin Infect Dis. 2016;62 Suppl 2:S96-S105.
41. Lundgren O, Svensson L. Pathogenesis of rotavirus diarrhea. Microbes Infect. 2001;3(13):1145-56.
42. Morris AP, Estes MK. Microbes and microbial toxins: paradigms for microbial-mucosal interactions. VIII. Pathological consequences of rotavirus infection and its enterotoxin. Am J Physiol Gastrointest Liver Physiol. 2001;281(2):G303-10.
43. Takata K, Matsuzaki T, Tajika Y. Aquaporins: water channel proteins of the cell membrane. Prog Histochem Cytochem. 2004;39(1):1-83.
44. Matsuzaki T, Suzuki T, Koyama H, Tanaka S, Takata K. Water channel protein AQP3 is present in epithelia exposed to the environment of possible water loss. J Histochem Cytochem. 1999;47(10):1275-86.
45. Hara-Chikuma M, Verkman AS. Aquaporin-3 functions as a glycerol transporter in mammalian skin. Biol Cell. 2005;97(7):479-86.
46. Phillips SF. Diarrhea: a current view of the pathophysiology. Gastroenterology. 1972;63(6):495-518.
47. Cao M, Yang M, Ou Z, Li D, Geng L, Chen P, et al. Involvement of aquaporins in a mouse model of rotavirus diarrhea. Virol Sin. 2014;29(4):211-7.
48. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, et al. Cell migration: integrating signals from front to back. Science. 2003;302(5651):1704-9.
49. Enomoto A. [Coordination of actin cytoskeleton and membrane transport in cell migration]. Seikagaku. 2008;80(3):233-40.
50. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007;8(11):857-69.
51. Goumans MJ, Liu Z, ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res. 2009;19(1):116-27.
52. Jiang Y, Liu H, Liu WJ, Tong HB, Chen CJ, Lin FG, et al. Endothelial Aquaporin-1 (AQP1) Expression Is Regulated by Transcription Factor Mef2c. Mol Cells. 2016;39(4):292-8.
53. Maiti D, Xu Z, Duh EJ. Vascular endothelial growth factor induces MEF2C and MEF2- dependent activity in endothelial cells. Invest Ophthalmol Vis Sci. 2008;49(8):3640-8.
54. Papadopoulos MC, Saadoun S. Key roles of aquaporins in tumor biology. Biochim Biophys Acta. 2015;1848(10 Pt B):2576-83.
55. Wei X, Dong J. Aquaporin 1 promotes the proliferation and migration of lung cancer cell in vitro. Oncol Rep. 2015;34(3):1440-8.
56. Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011;2(12):1097-105.
57. Lee SH, Jeong D, Han YS, Baek MJ. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. 2015;89(1):1-8.
58. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011;437(2):169-83.
59. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 2001;22(4):201-7.
60. Foubert P, Varner JA. Integrins in tumor angiogenesis and lymphangiogenesis. Methods Mol Biol. 2012;757:471-86.
61. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005;9(2):267- 85.
62. Bae WY, Choi JS, Kim JE, Jeong JW. Cinnamic aldehyde suppresses hypoxia-induced angiogenesis via inhibition of hypoxia-inducible factor-1α expression during tumor progression. Biochem Pharmacol. 2015;98(1):41-50.
63. Sakamoto Y, Hisatsune A, Katsuki H, Horie I, Isohama Y. Aquaporin 5 increases keratinocyte- derived chemokine expression and NF-κB activity through ERK activation. Biochem Biophys Res Commun. 2014;448(4):355-60.
64. Osuka K, Watanabe Y, Usuda N, Atsuzawa K, Aoyama M, Niwa A, et al. Activation of Ras/MEK/ERK signaling in chronic subdural hematoma outer membranes. Brain Res. 2012;1489:98-103.
65. Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis. 1992;51(7):919-25.
66. Williams JM, Duckworth CA, Watson AJ, Frey MR, Miguel JC, Burkitt MD, et al. A mouse model of pathological small intestinal epithelial cell apoptosis and shedding induced by systemic administration of lipopolysaccharide. Dis Model Mech. 2013;6(6):1388-99.
67. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197- 216.
68. Medzhitov R. Innate immunity: quo vadis? Nat Immunol. 2010;11(7):551-3.
69. Matsuzawa A, Saegusa K, Noguchi T, Sadamitsu C, Nishitoh H, Nagai S, et al. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol. 2005;6(6):587-92.
70. Wi SM, Moon G, Kim J, Kim ST, Shim JH, Chun E, et al. TAK1-ECSIT-TRAF6 complex plays a key role in the TLR4 signal to activate NF-κB. J Biol Chem. 2014;289(51):35205-14.
71. Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T, et al. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem. 1994;269(18):13289-95.
72. Rahman I, Gilmour PS, Jimenez LA, Biswas SK, Antonicelli F, Aruoma OI. Ergothioneine inhibits oxidative stress- and TNF-alpha-induced NF-kappa B activation and interleukin-8 release in alveolar epithelial cells. Biochem Biophys Res Commun. 2003;302(4):860-4.
73. Yoon SW, Chun JS, Sung MH, Kim JY, Poo H. alpha-MSH inhibits TNF-alpha-induced matrix metalloproteinase-13 expression by modulating p38 kinase and nuclear factor kappaB signaling in human chondrosarcoma HTB-94 cells. Osteoarthritis Cartilage. 2008;16(1):115- 24.
74. Meers GK, Bohnenberger H, Reichardt HM, Lühder F, Reichardt SD. Impaired resolution of DSS-induced colitis in mice lacking the glucocorticoid receptor in myeloid cells. PLoS One. 2018;13(1):e0190846.
75. Hamady ZZ, Scott N, Farrar MD, Lodge JP, Holland KT, Whitehead T, et al. Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut. 2010;59(4):461-9.
76. Hoshino T, Tsutsumi S, Tomisato W, Hwang HJ, Tsuchiya T, Mizushima T. Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem. 2003;278(15):12752-8.
77. Takeuchi T, Tanaka K, Nakajima H, Matsui M, Azuma YT. M2 and M3 muscarinic receptors are involved in enteric nerve-mediated contraction of the mouse ileum: Findings obtained with muscarinic-receptor knockout mouse. Am J Physiol Gastrointest Liver Physiol. 2007;292(1):G154-64.
78. Vijayan V, Mueller S, Baumgart-Vogt E, Immenschuh S. Heme oxygenase-1 as a therapeutic target in inflammatory disorders of the gastrointestinal tract. World J Gastroenterol. 2010;16(25):3112-9.
79. Lee B, Moon KM, Kim CY. Tight Junction in the Intestinal Epithelium: Its Association with Diseases and Regulation by Phytochemicals. J Immunol Res. 2018;2018:2645465.
80. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014;14(3):141-53.
81. Ricanek P, Lunde LK, Frye SA, Støen M, Nygård S, Morth JP, et al. Reduced expression of aquaporins in human intestinal mucosa in early stage inflammatory bowel disease. Clin Exp Gastroenterol. 2015;8:49-67.
82. Zhao G, Li J, Wang J, Shen X, Sun J. Aquaporin 3 and 8 are down-regulated in TNBS-induced rat colitis. Biochem Biophys Res Commun. 2014;443(1):161-6.
83. Tsang KW, Leung JC, Tipoe GL, Leung R, Yan C, Ooi GC, et al. Down-regulation of aquaporin 3 in bronchiectatic airways in vivo. Respir Med. 2003;97(1):59-64.
84. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol. 2004;13(4):193-222.
85. Ikarashi N, Baba K, Ushiki T, Kon R, Mimura A, Toda T, et al. The laxative effect of bisacodyl is attributable to decreased aquaporin-3 expression in the colon induced by increased PGE2 secretion from macrophages. Am J Physiol Gastrointest Liver Physiol. 2011;301(5):G887-95.
86. Hara-Chikuma M, Verkman AS. Roles of aquaporin-3 in the epidermis. J Invest Dermatol. 2008;128(9):2145-51.
87. Thiagarajah JR, Zhao D, Verkman AS. Impaired enterocyte proliferation in aquaporin-3 deficiency in mouse models of colitis. Gut. 2007;56(11):1529-35.
88. Horie I, Maeda M, Yokoyama S, Hisatsune A, Katsuki H, Miyata T, et al. Tumor necrosis factor-alpha decreases aquaporin-3 expression in DJM-1 keratinocytes. Biochem Biophys Res Commun. 2009;387(3):564-8.
89. Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50(8):103.
論文の公開元へ
